Navigation Links
Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
Date:10/1/2007

Study Data Show Patients with Moderate to Severe Psoriasis Who Responded to Anti-IL-12/23 ABT-874 after 12 Weeks of Treatment, Maintained Response at

24 Weeks

BUENOS AIRES, Argentina, Oct. 1 /PRNewswire-FirstCall/ -- Results from an extension to a Phase II study evaluating the effectiveness of Abbott's (NYSE: ABT) investigational anti-IL-12/23 antibody ABT-874 showed that a majority of patients who initially responded to treatment maintained a high level of response following discontinuation of therapy. In the study, patients who achieved 75 percent improvement in psoriasis signs and symptoms (PASI 75) at 12 weeks stopped receiving ABT-874. At 24 weeks, more than two- thirds of these patients maintained at least 50 percent improvement (PASI 50). The Phase II study, conducted in patients with moderate to severe psoriasis, will be presented at the World Congress of Dermatology in Buenos Aires.

Phase II results presented earlier this year at the Society for Investigative Dermatology (SID) Meeting showed ABT-874 reduced psoriasis symptoms significantly in the majority of patients treated. At 12 weeks, at least 90 percent of patients with moderate to severe psoriasis achieved 75 percent improvement in psoriasis signs and symptoms in all but the lowest dosing groups receiving ABT-874, versus 3 percent of patients receiving placebo. Also, more than half of patients achieved 90 percent improvement, in the same four of five ABT-874 dosing groups, versus 0 percent of those receiving placebo.

"ABT-874 represents a novel approach to treating psoriasis, targeting a part of the inflammatory response that is not addressed by any therapy available today," said Alan Menter, MD, Chair,
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
6. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
7. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
10. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
11. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)...  BioPhotas, Inc., an FDA registered medical device manufacturer ... to treat skin, muscle and joint conditions, today announced ... to provide BioPhotas, flagship product, the Celluma, ... Commenting on the alliance, Patrick ... Celluma at the Warrior Hope and Care Center had ...
(Date:3/5/2015)... -- CANTEL MEDICAL CORP. (NYSE: CMN ) will ... 2015 on Thursday, March 12 before the market opens, and ... AM ET. To participate in the conference ... the beginning of the call. If you are unable to ... from Thursday, March 12, 2015 through midnight on May 12, ...
(Date:3/5/2015)... , March 5, 2015   ndd Medical ... testing (PFT) that employs precise ultrasound technology, announced that ... event held by the San Antonio Pulmonary Fibrosis Support ... (ILD) or pulmonary fibrosis (PF), as well as those ... a footprint of a mere 12 square inches, EasyOne ...
Breaking Medicine Technology:BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 3
... 22, 2010 Pfizer Inc (NYSE: PFE ... to both the United States Food and Drug Administration ... the use of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine ... and older for the prevention of pneumococcal disease caused ...
... Dec. 22, 2010 Haemonetics Corporation (NYSE: ... Chief Executive Officer, will present at the J.P. Morgan ... 2011 at 1:30 pm Pacific time.  The ... at http://jpmorgan.metameetings.com/webcasts/healthcare11/directlink?ticker=HAE .  The webcast ...
Cached Medicine Technology:Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older 2Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older 3Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older 4Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older 5
(Date:3/6/2015)... (PRWEB) March 06, 2015 “ Pokemini ” ... which features the latest and coolest mobile applications on the ... expert and host of NewsWatch, conducted the app review and ... game. , Over the last couple of years, mobile ... to the game. For example, Candy Crush allows users to ...
(Date:3/6/2015)... Ticket Down is a reputable source for ... the Moda Center. After being away from the touring ... no signs of letting up on his “Garth Brooks World ... wife, Trisha Yearwood, to venues around the United States. The ... acclaimed tour to the Moda Center in Portland, OR. The ...
(Date:3/6/2015)... As the Muscular Dystrophy Association continues to enhance its ... two new Scientific Program Officers, Amanda Haidet-Phillips, Ph.D and ... Pavlath, Ph.D, who joined MDA late last year as ... will lead MDA as it accelerates new front-line discovery ... of neuromuscular and motor neuron diseases. , ...
(Date:3/6/2015)... CA (PRWEB) March 06, 2015 US ... of three Maryland camps – two non-contact specialty camps ... be run by Perfect Performance Training, located at Bowie ... focus on developing position specific skills, speed and strength ... hosted at Salisbury University with Marvin Graves, former quarterback ...
(Date:3/6/2015)... California (PRWEB) March 06, 2015 Johnson ... million jury verdict on March 5, 2015 in Superior ... According to court documents, a jury of 12 awarded ... suffered from being implanted with an Ethicon TVT Abbrevo ... nine men and three women also awarded $5 million ...
Breaking Medicine News(10 mins):Health News:A Kawaii Social Game was Featured on NewsWatch Television on February 26, 2015 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3
... for first time treatment of advanced lung cancer in ... randomised study on lung cancer patients led by Dr.Alan ... at Vanderbilt-Ingram Cancer Center. ,Nearly 900 patients ... the trial. None of them had received any previous ...
... the world today, Britain had to face the embarrassment of ... week. //In a recent report by CABE it was brought ... population can be declared obese and overweight. ,The ... headquarters in London works towards improving people's quality of life ...
... to investigate a botched cataract surgery camp at the Guwahati ... ,Health Minister Himanta Biswa Sarma said the enquiry would be ... and was expected to submit the report in three months. ... hence instituted a judicial probe to fix responsibility for the ...
... Virus type C (GBV-C) protects against HIV infection is now ... Iowa// City Health Care System and the University of Iowa ... growing in cell models. ,The team found that ... NS5A greatly slows down HIV from replicating in cells grown ...
... Hospital have developed a revolutionary treatment for dementia.// ... Research Centre George Razay merely merely draining fluid from ... 5000 Tasmanians are affected by dementia and the figure ... ,20 patients, equal number of men and women ...
... In order to restrict the use animals for the ... new techniques are being developed by researchers at the ... as a financial grant. ,Gauging the carcinogenic effects ... which further necessitates the use of live animals to ...
Cached Medicine News:Health News:Judicial Probe Ordered for Botched Eye Surgery Camp 2Health News:Study IDs Protein That Inhibits HIV From Growing In Cell Cultures 2Health News:Study IDs Protein That Inhibits HIV From Growing In Cell Cultures 3Health News:Grant Encourages Drug Testing Sans Animals 2
The cordless Simon Dermatome with rechargeable battery is used to harvest split-thickness skin grafts and for debridement....
Forceps with round handle, straight...
Castroviejo microscopic needle holder...
Microscopic scissors, curved...
Medicine Products: